ALZAI and Linus Health Explore AI-Driven Collaborations Aimed at Early Identification of Alzheimer's Disease Risk and Cognitive Impairment

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - August 11, 2026) - ALZAI Health Corp. (TSXV: ALZI) is pleased to announce that it has entered into a Memorandum of Understanding (MOU) with Linus Health, an AI-driven brain health company focused on early detection and proactive intervention. The companies intend to explore opportunities to use their complementary technologies to support earlier identification and assessment of Alzheimer's disease risk and cognitive impairment, as well as related triage and care pathways.*

ALZAI and Linus will look at ways to combine ALZAI's AI-driven Alzheimer's disease risk identification algorithm with Linus Health's RADAR risk stratification algorithm, digital cognitive assessments, and clinical decision support. Potential applications include integrated solutions supporting clinical trial recruitment, funded research initiatives, healthcare provider engagement, and dementia care workflows.

The two risk-stratification approaches draw on complementary data already available in health records. ALZAI's algorithm uses routine bloodwork and demographic data already present in the medical record to stratify disease risk without requiring a new test. Linus Health's RADAR (Risk of Alzheimer's and Dementia AlgoRithm) builds on and improves the published and validated eRADAR model, using electronic health record (EHR) and/or claims data that include diagnostic, medication, and healthcare-utilization signals. Linus Health's Core Cognitive Evaluation™ (CCE), which incorporates the Digital Clock and Recall (DCR™), can then assess current cognitive performance, with results and recommended next steps returned to the clinician within the existing care workflow.

The collaboration will focus on opportunities with pharmaceutical companies, contract research organizations (CROs), healthcare providers, healthcare systems, and research institutions to improve patient identification, optimize clinical trial recruitment, support clinical workflow integration, and advance earlier identification of individuals at elevated risk for Alzheimer's disease.

"We believe meaningful innovation in Alzheimer's disease requires collaboration across complementary technologies," said Hayim Raclaw, CEO of ALZAI Health. "Linus Health has established itself as a leader in digital cognitive assessment and brain health solutions. We believe that combining their capabilities with ALZAI's AI-driven disease-risk identification algorithm could support the development of more integrated solutions. We look forward to exploring commercial and research opportunities that could advance earlier identification and patient care."

Schreibe Deinen Kommentar